News
Extended-release clonidine (Kapvay) is an oral drug used to treat ADHD. Learn how it works, its side effects, drug interactions, and more.
Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...
Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron ...
Hosted on MSN8mon
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug - MSNThe EU Commission said Teva's actions may have prevented significant savings by countries across Europe, with other versions of the drug possibly 80% cheaper than Copaxone. Teva will have to pay a ...
Hosted on MSN5mon
Teva sues CMS over Medicare drug price negotiationsTeva Pharmaceutical Industries' (NYSE:TEVA) U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act. In its lawsuit filed in D.C ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller’s top stock picks with huge ...
Teva Pharmaceutical Industries Limited TEVA announced a funding agreement with Royalty Pharma RPRX to accelerate the development of its key pipeline candidate, olanzapine (TEV-‘749), a long ...
The European Union fined Israel’s Teva Pharmaceutical 462.6 million euros, saying it abused its market position in a way that might have delayed competitors from entering the multiple sclerosis ...
Both 20mg and 30mg tablets of Teva’s branded ADHD drug Adderall are currently on backorder in the U.S., with the company eyeing a release date in early- to mid-August, according to the American ...
Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...
Teva Pharmaceutical will pay $225 million and divest its copycat version of a cholesterol drug as part of its settlement of price-fixing charges, the U.S. Department of Justice said on Monday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results